Fresolimumab

From Self-sufficiency

Revision as of 23:08, 23 February 2010 by Anypodetos (Talk) (Added mab_type, updated source)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Fresolimumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	TGF beta 1, 2 and 3
Identifiers
CAS Number	948564-73-6
ATC code	none
Chemical data
Formula	C₆₃₉₂H₉₉₂₆N₁₆₉₈O₂₀₂₆S₄₄
Molar mass	144.4 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Fresolimumab is a human monoclonal antibody^[1] and an immunomodulator, developed by Genzyme. It is intended for the treatment of idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, and cancer,^[2]^[3] but has not entered clinical trials as of October 2009^[update].^[4]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

v t e Human monoclonal antibodies ("-u-")
"-limu-" (immune system)	immunosuppression: Adalimumab, Atorolimumab, Fresolimumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab immune activation: Ipilimumab, Tremelimumab other: Bertilimumab, Zanolimumab
"-kinu-" (interleukin as target)	Briakinumab, Canakinumab, Ustekinumab
"-tumu-"/"-tu-" (tumor)	Adecatumumab, Belimumab, Cixutumumab, Conatumumab, Figitumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Necitumumab, Ofatumumab, Olaratumab, Panitumumab, Pritumumab, Robatumumab, Votumumab, Zalutumumab
"-osu-" (bone)	Denosumab
"-mulu-" (musculoskeletal)	Stamulumab^†
"-fungu-" (fungal)	Efungumab
"-viru-" (viral)	Exbivirumab, Foravirumab, Libivirumab, Rafivirumab, Regavirumab, Sevirumab, Tuvirumab
"-bacu-" (bacterial)	Nebacumab, Panobacumab, Raxibacumab
"-ciru-" (cardiovascular)	Ramucirumab
"-neru-" (neurologic)	Gantenerumab
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.